PURPLE PAMPERS
The Inside True Story Behind the Purple Pill
by Harry Elwardt, N.D., Ph.D.
Let
me begin by asking all of you, “What do you think is the #1 selling drug in
the
What
I wish to do in this Life Saving Report is expose you to the
truth about this purple pill.
Tell you about how it came to become #1 and also the Cloak &
Dagger process involved by Big Pharma to
drive a new drug to become a #1 contender.
What
prompted this Life Saving Report and my choice for the title is I
recently ran across a news article reported on December 19th in the Associated
Press, that
talks about people who take widely used heartburn drugs like Prilosec, Prevacid and Nexium may be trading heartburn for another problem: a
potentially dangerous diarrhea caused by Clostridium difficile
bacteria.
C-diff,
as it's known, causes severe diarrhea and the
intestinal inflammation, colitis. Here
is the article:
Popular Heartburn
Drugs Linked To Diarrhea
People
on popular prescription heartburn drugs — Prilosec, Prevacid and Nexium — seem more
prone to getting a potentially dangerous diarrhea caused by the bug
Clostridium difficile, new research shows. C-diff, as
it’s known, can cause severe diarrhea and crampy intestinal inflammation called colitis.
Dr.
Sandra Dial and colleagues at
Patients with prescriptions for powerful acid-fighters called proton pump inhibitors, which include Prilosec and Prevacid, were almost three times more likely to be diagnosed with the bug than those not taking the drugs. Those on less potent prescription drugs called H2 receptor antagonists, which include Pepcid and Zantac, were two times more likely than nonusers to get C-diff infections.
The
widely used and heavily promoted drugs reduce levels of gastric acid that can
keep C-diff germs at bay.
Dr.
L. Clifford McDonald, a researcher at the federal Centers for Disease Control
and Prevention, said proton pump inhibitors recently were implicated in a
C-diff outbreak at a hospital and nursing homes in
“It’s
not surprising in my mind that there could be some association” with
acid-fighting drugs, said McDonald, who was not involved in Dial’s study. If
there is, “I do think it would be very important because, boy, everyone and
their brother seems to be on them.”
Most study patients hadn’t been recently hospitalized and weren’t taking antibiotics, which both can increase risks for C-difficile infections. Also, most patients hadn’t been diagnosed with ulcers or acid reflux, so it’s possible many simply had heartburn, Dial said. “Heartburn in and of itself isn’t dangerous,” and can often be treated with less potent drugs, Dial said.
Her
study appears in Wednesday’s Journal of the American Medical Association.
A
co-author is a consultant for AstraZeneca PLC, which
markets Prilosec and Nexium,
and Altana Pharma, which
makes and markets another prescription heartburn drug, Protonix,
in
AstraZeneca spokeswoman Cindy Callaghan said patient safety is the company’s top
priority and that the findings are not the final word. “Further research is
needed in this particular area to determine the validity of a potential link,”
she said.
2005 The Associated
Press
All
righty then!
Let
me begin by saying that what the spokeswoman for AstraZeneca
said about safety being the company’s top priority almost brought a tear to my
eye…actually the tear was caused by me gagging! As time goes on I will expose you to the
truth about Big Pharma. You will learn that the number one
priority of every pharmaceutical company is not in the safety of the consumer
but increasing the shareholders profits.
But
I believe the best answer for this new problem might just be for a doctor to
write a prescription for some Purple Pampers to go along with his
prescription for the Purple Pill!
At
the end of this Health E-Alert I will provide you with some natural
remedies you can use to overcome the problem of heartburn, but now let’s
investigate how our world became so dependent on the Purple Pill.
Big
Pharma Strategy:
Create A Disease…And They Will Come!
Gertrude
was sitting with her husband in their
Like most of the TV commercials for prescription drugs
that kept Brokaw, Rather, and
The 79-year-old, who didn't want her last name used, is a longtime sufferer of serious heartburn. So she's among the many who hail the miracle powers of the original Purple Pill, Prilosec. That drug stripped misery from the lives of millions and became the world's best-selling prescription drug - and the number one medication prescribed for seniors - taking in $6 billion a year. Prilosec is so good, and patients so attached to it, that doctors jokingly call it "purple crack."
It's an expensive habit, about $4 for each daily pill, or $1,500 a year. General Motors alone spent $55 million on Prilosec for its workers last year. The drug has been the ultimate cash cow for its maker, AstraZeneca.
But by now the cow should have run dry. The main patent on Prilosec expired and under normal circumstances, that would have triggered the arrival of a generic version on the market, followed by a host of generic rivals. With so much low-cost competition, we would all be enjoying lower drug costs. But that didn't happen.
Through lawsuits, the makers of Prilosec have managed to keep the generics at bay while unleashing a half-a-billion-dollar marketing blitz to move people off Prilosec and onto Nexium, their costly, patent-protected new Purple Pill, which even their own studies show to be barely more effective than the original.
How and why AstraZeneca has been able to keep the purple profits flowing sheds more light on the nation's prescription drug crisis than reams of policy papers and congressional testimony. The same tactics are being used by just about all the big pharmaceutical companies, which are under intense shareholder pressure to maintain their best-in-business profits as the patents on about 20 blockbuster drugs expire over the next couple of years.
That explains the ads for the new drug Clarinex that are everywhere, right down to the white CVS bag your last prescription came in. Schering-Plough has been feverishly working to move the itchy-eyed onto Clarinex and off its omnipresent Claritin, whose patent expired. Ditto for Forest Laboratories' new antidepressant, Lexapro, the spawn of Celexa, whose patent is set to expired at the beginning of 2004.
But
given the sheer numbers involved and its still-evolving nature, the Purple
Pill may be our best case study of the forces driving up prescription drug
costs. It's the story of a wondrous medical advance that brought relief to
millions and significantly reduced the need for surgery. But it's also the
story of the steroid-injected marketing muscle that has ensnared, among others,
"This
is a locomotive that's barreling down the tracks, and you either
get out of the way, get on board, or get squished," says Dr. James Richter, a
First things first: This prescription drug crisis you hear everyone squawking about - it's really so avoidable. We Americans are on pace to spend nearly $200 billion on our meds this year. That's more than the federal government paid last year for education, agriculture, transportation, and the environment combined.
In
any rational world, that sum would not just cover our current pill habit but
would also allow us to pick up the drugstore tab for all those senior citizens
paying out of pocket for their high blood pressure and arthritis pills. We
could spare them the indignity of those Greyhound-bus narc-runs
to
Who's responsible for the fact that prescription drug spending continues to rise 15 to 20 percent a year, doubling every five years?
The big pharmaceuticals have certainly lost much of their "best and the brightest - making life better for you" luster. That's perhaps inevitable when you pour more money into peddling your newest product than Nike does its sneakers. But there's plenty of blame to go around. The government allows drug companies to control the testing of new drugs, designing trials to suit their interests, not the consumers'.
HMOs
and hospitals, under their own bottom-line pressures, make deals that help the
drug manufacturers move patients to new, expensive
drugs when cheaper, older ones might do fine. Doctors operate in a world where
drug maker freebies like Red Sox tickets, Four Seasons dinners, and
Now go to your bathroom and look in the mirror. There's a good chance that you're one of those shareholders demanding higher profits from the pharmaceutical companies, even if you don't know it. (Think about those pharmaceutical-dense mutual funds you're counting on to pay your kid's college tuition.) Now open the medicine cabinet.
Do you see a bottle of Clarinex? Or maybe there's still a vial of Vioxx, the new drug you pressed your doctor to prescribe for your arthritis, because it did wonders for Dorothy Hamill. ("Look how easily she can lace up her skates now!") Forget the fact that several studies have questioned whether it's any more effective than over-the-counter Advil and now has been pulled from the market because of its link to heart attacks…OOPS! Or maybe there's some Viagra on the shelf. And let's just say you're half Bob Dole's age and haven't been treated for prostate cancer.
"We're in this perfect storm of forces that conspire to make it a very expensive time," says Dr. Thomas Lee, medical director for Partners Community HealthCare, the largest physician network in Massachusetts. He ticks off some of the factors driving up costs.
First, all that research after World War II didn't begin to bear fruit until the 1980s and 1990s. Now we have effective medicines for all kinds of conditions, including ways to treat impotence and depression that don't involve a couch.
Second,
we've got all these baby boomers passing through middle age and either getting
chronic disease or doing everything to avoid it. "Baby boomers don't want
to accept that they will ever die," says Lee. Just since 1995, his
Partners group has seen a nearly one-fifth increase in the number of patients
taking medication regularly.
And last, we've got pharmaceutical companies trying to get the maximum market for the drugs they spent so much to develop. "They're not interested in fine-tuning to make sure the people who get the new expensive drugs are those who will really benefit from it," Lee says. "They want everyone for whom there is a reasonable justification."
This is how it used to be: The boss would keep four bottles of Maalox in his desk. Every three hours, he'd grab one from his bottom drawer and take a swig. Short of surgery, there wasn't much else he could do to treat his heartburn, which is the main symptom of gastroesophageal reflux disease.
Food travels from the mouth, down the esophagus, and through a sphincter muscle to get into the stomach. Because the stomach is filled with acid potent enough to take the rust off your car, the sphincter is supposed to relax only to let food and drink in. But for the 40 million Americans who suffer chronic heartburn, the muscle relaxes way too often.
So the acid regularly flows up into the esophagus, causing a noxious burning in the upper abdomen and lower chest, especially after eating that third slice of deep-dish pepperoni pizza.
In 1977, the Tagamet revolution began. Whereas the common antacids like Maalox and Tums neutralized acid, prescription Tagamet blocked it. It made a huge difference. Still, there was a group of people who needed something more powerful than Tagamet and its successors, included in a class of drugs that came to be known as H2 blockers.
In 1989, that power came in spades and in the unforgettable shade of purple. Prilosec was the first proton pump inhibitor, or PPI. H2 blockers stop acid at one of three possible sites in the cells of the stomach, but PPIs block it at the final site of production. They're a fail-safe means of turning off the stomach-juice spigot before it backs up into the esophagus. "Prilosec gave physicians a sense of power, a sense that we can cure you," recalls Dr. James Reichheld, an Andover gastroenterologist.
Still, Prilosec was really just a niche drug when the Swedish company Astra AB (it later merged with the British firm Zeneca) teamed up with the US firm Merck to launch it in the United States. The US Food and Drug Administration approved it for just two indications, or uses, for which there was a particularly limited pool of customers. Heartburn wasn't one of them. And there were fears that the drug might have cancer risks.
As most drug manufacturers do, Astra continued clinical trials to win approval for new indications to put on the Prilosec label - it eventually reached eight - and increase its customer base. (Remember, Viagra was originally developed to treat angina; that whole erection thing was just a pleasant surprise.)
Prilosec continued to grow. Then, in 1997, the FDA tied a bow on a big fat gift to the pharmaceutical industry: relaxed rules for drug advertising. It's not that direct-to-consumer advertising was a new phenomenon.
Back in 1708, Boston apothecary Nicholas Boone bought the first patent-medicine ad, announcing in the News-Letter that he would be selling Daffy's Elixir Salutis for four shillings and sixpence a bottle. It's just that, prior to 1997, drug makers were required to disclose so many side effects on their ads as to make TV spots unworkable. The new FDA rules allowed them to make their claims unimpeded, as long as they offered a phone number or Web site or referenced a magazine ad where consumers could get the fine print.
Prilosec was the perfect drug to market on TV. Millions of people have gastric problems, and many were no doubt feeling the pain right as the commercial flashed on the screen in front of them. Here was this incredibly effective new medication waiting to change their lives. And when they later found themselves sitting on a doctor's padded exam table, they didn't even have to recall the drug's name. All they had to remember was its color.
Soon, Purple Pill ads were everywhere - on TV, on the Web, even on the floor of New York's bus terminals. Hall of Fame pitcher Jim Palmer was telling anyone who would listen how the drug had saved his broadcasting career. All those forces helped catapult Prilosec to the top. In 1998, it became the first drug ever to hit $5 billion a year in worldwide sales, and it didn't stop there.
Prilosec's success prompted several competitors to come forward with their own PPIs: Prevacid (TAP/Abbott), Aciphex (Eisai/Johnson & Johnson), and Protonix (Wyeth). And, of course, Prilosec me-too'ed itself last year with the launch of Nexium.
It's probably not surprising that me-toos have become so irresistible. Trying to come up with genuine breakthroughs is a lot harder, riskier, and more expensive. A recent study from Tufts University's Center for Drug Development found that it costs an average of $802 million to develop and win approval to bring a new drug to market in the United States.
Why so much? Take a drive out to Waltham to AstraZeneca R&D Boston, the company's new three-winged structure of Minnesota limestone. Throughout four floors of bright, impeccable labs, sneaker-clad scientists in white coats are on the hunt for genuinely novel medicines - not me-toos - to treat cancer and infection. In a field that has come to be dominated by talk of profits and patents, the vital work going on behind these glass walls - testing and retesting compounds, replicating DNA - puts some of the inspiring sheen back on the pharmaceutical industry.
If I were to ask Hans Nilsson, the Swedish native who oversees the Waltham site, why it's so hard to hatch a new drug. He walks up to the white board in his office and makes a series of drawings: enzyme, membrane, cell, tissue, organ, mouse, cat, dog, monkey, human, cluster of humans.
Drug discovery, he says, is the attempt to make a series of increasingly complex connections to get to the finish line. If the connection works from, say, cell to tissue, you can move on. More often than not, it won't, so you have to return to an earlier step. Even at the end, when you've shown a compound to be effective and safe in thousands of humans, you might get one whose liver fails because of toxicity caused by the drug. So you start again.
The vast majority of attempts will never get to the approval stage. The trick is knowing how long to stick with it or when to pack it in. Research on omeprazole, the generic name for Prilosec, "started in the late 1960s," Nilsson says. "It was launched 20 years later. Twenty years. You never know how close you might be."
To those who question how a company like AstraZeneca can justify the staggering profits it collects from a drug like Prilosec, Nilsson again points to his sketch. "This is the answer." AstraZeneca spent $2.7 billion on R&D last year. Then again, the company also reported profits of $4.2 billion.
Still, all the competition from the me-too drugs should bring down overall health care costs, right? Maybe in any other world. But the exorbitant marketing campaigns used to launch competitors, like Prilosec me-too Prevacid, tend to drive up costs. They increase the patient population, sucking up customers who might do fine on 50-cents-a-day generic H2 blockers and moving them into the new, more powerful PPI club, whose daily admission fee runs seven to eight times higher.
James Richter, the longtime Massachusetts General Hospital gastroenterologist who last month became chief medical officer of Caritas Christi Health Care System, puts it this way: "You go to the rental car counter, and the company's paid for it, and you can get a Hyundai or a Cadillac. So you take the Cadillac even though the other would be sufficient."
There's a phenomenon associated with PPIs called acid rebound. Because the medicine puts a brake on the acid-producing pumps in your stomach, when you stop taking it, that built-up acid can be unleashed, says Ferris.
Even if there's no full-scale rebound, most people have some recurrence of symptoms because the PPIs were powerful enough to let them resume bad habits, such as eating fatty foods. When that power's gone, they start paying for their sins. Ferris and his associates recommended extra doses of the H2 blockers at the beginning, knowing that rebound is usually temporary. But few people made it that far.
What's clear is that if you want to restrict this expensive drug to only those people who really need it, you have to start at the beginning, before they've test-driven the Cadillac. But all those TV commercials make that next to impossible. Most people have a spouse or a cousin or a mechanic who's on the Purple Pill and speaks evangelically about it ("I can eat chili again!"), so they enter the doctor's office knowing what they want. Richter explains how it works: "They come in and say: 'My husband takes Nexium. Do you think that would work well for me?' I say, 'Yes, but have you tried Tagamet? It doesn't appear that you're having symptoms that frequently.' But they say, 'Nexium and Prilosec seem to work really well.' So I say, 'Fine.' "
Besides cost, there's no downside to taking Nexium or Prilosec. But if it takes a doctor 15 minutes to talk a patient out of a more expensive drug - and that's pretty much all the time the doctor has with the patient to begin with - it's not a practical investment.
And this calculation comes from Richter, who for 20 years has refused to meet with drug company sales representatives, on principle. Think about how much more quickly a doctor might offer up the new drug if he had the Nexium golf-scoring software loaded onto his Palm Pilot or if the Nexium drug rep had just brought by lunch for the staff when he arrived to restock the sample cabinet.
Throughout the summer and fall, David Calabrese had a ritual to start his day. He would walk into his Roxbury office and check his e-mail in search of an announcement that the generic Prilosec had finally been launched. Calabrese is the pharmacy director for a network of 2,500 doctors associated with Beth Israel Deaconess Medical Center and several other medical facilities. Last year, Prilosec was the biggest item ($6 million) on his outpatient drug budget. A generic offers the promise of cutting that tab by a third in the first year and much more in subsequent years.
AstraZeneca's Prilosec patent expired in October 2001. So Calabrese and many pharmacy directors like him across the country - for HMOs, physician groups, and hospitals - built those expected savings into their drug budgets the following year. The fact that they have not materialized may well help drive up everyone's insurance premiums next year, he says. It doesn't matter if you never get heartburn. You could be one of those people who can guzzle a whole bottle of Tabasco sauce and not so much as burp. You're still affected by the Purple Pill. The overall costs to the system are that big.
Late one Friday night, Calabrese got the e-mail message, but it didn't say what he had expected. He quickly forwarded it to a few co-workers, putting "Ugh" in the heading.
AstraZeneca had long ago filed suit against four companies planning to produce generic Prilosec, claiming infringement not on the main patent but on secondary ones. The trial began last December in a federal court in New York and dragged on until June. Most analysts expected AstraZeneca to lose, and the company's stock took a beating. But after the judge issued her ruling on October 11, the company's stock shot up.
She ruled that three of the four generic companies had infringed on AstraZeneca's patented method for inserting a "subcoating" between the main Prilosec molecule and its purple shell. Critics had scoffed at this claim, pointing to a host of drugs that have similar subcoatings. But a patent is a patent, the judge ruled, and this one doesn't expire until 2007.
AstraZeneca spokesman Jim Coyne called the decision a "vindication." The case, he said, "has always been about defending our intellectual property." The company's chief executive, Tom McKillop, told The Financial Times of London that the court action clearly paid off for his company: "Our defense strategy has already given us longer exclusivity over the last few months. And now it is likely to give us some months more and maybe even a lot longer than that."
The two generic companies poised for a quick, aggressive launch were shut out. Earlier this month, they announced that, in exchange for a share of the profits, they would assist the one tiny firm that the judge said could launch a generic Prilosec. Still, AstraZeneca may appeal the part of the ruling that gave that firm the green light. Says Calabrese: "There's a flicker of light at the end of the tunnel, but I'm not very confident we'll see a generic Prilosec anytime soon."
The world's other big pharmaceutical companies cheered the ruling, and their stock responded accordingly. Most are in the same patent boat as AstraZeneca. The 1984 Hatch-Waxman Act awarded drug makers 17 years of patent protection (later extended to 20 years) for drugs they create. The clock usually starts ticking long before a drug is launched. These days, when the 20 years is up, brand-name drug makers do not allow their blockbusters to go off patent quietly into the night. They file for all sorts of extensions.
And they have become increasingly savvy in obtaining patents for every conceivable feature of a drug, from its coating to how it combines with other drugs to its color. Other brand-name companies, like the makers of Prozac, lost their patent infringement cases. But AstraZeneca's victory is a strong sign that it can pay to take generics to court.
Meanwhile, all the court delays have given AstraZeneca time to move market share to Nexium, and that's where hospitals like Mass. General and Brigham and Women's come in. In exchange for getting Nexium at a fantastic discount, the hospitals agreed to make it their primary PPI. The switch will save Mass. General alone more than $300,000 a year. And the price discount is clearly worth it for AstraZeneca, since patients will be discharged on Nexium, residents will be trained on Nexium, and doctors across the country will be told that Nexium is the first choice of world-famous Mass. General.
AstraZeneca spent $478 million on its Nexium promotional campaign, according to IMS Health, and hired an additional 1,300 sales reps just for the new Purple Pill, according to Scott-Levin Consulting, a health care research firm. The push has been incredibly effective. Some 42 percent of Prilosec prescriptions have been converted to Nexium, according to data from the investment firm Dresdner Kleinwort Wasserstein.
Nexium is actually just one-half of the molecule that makes up Prilosec. The theory is that it improves the efficacy of a drug when its most effective part is isolated, in this case the "S isomer." Many specialists doubt this claim. Nonetheless, this route to a new product is becoming more common in the industry.
Dr. Doug Levine, AstraZeneca's executive director for gastrointestinal clinical research, says Nexium represents a clear improvement over Prilosec. But in most of the company's trials, the effects of 40 milligrams of Nexium were compared against 20 milligrams of Prilosec. In the two instances where they were compared at equal strength, only one showed a statistical difference, and that was a 3 percent shorter healing time.
Dr. Jerry Avorn, chief of the Brigham's pharmacoepidemiology division, says flatly, "Nexium is not at all better in any meaningful way than Prilosec." One of the nation's leading experts in the study of physician prescribing patterns, Avorn has made it his life's work to try to outsmart the drug companies.
Asked why his hospital decided to take the Nexium deal, he leans back in his chair, scratches his Abe Lincoln-style beard, and sighs. Noting that he didn't make the decision, he says he does understand it. Hospitals are under incredible pressure to keep their costs down.
A deal like this could prevent the Brigham from having to lay off nurses. "It's not like anybody is taking home extra money in a valise at the end of the month by doing this," Avorn says. But he acknowledges the "bad outcome" it produces: a new cycle of patients with unnecessarily higher drug tabs.
It's yet another sign of what's wrong with our health care system, he says, and why fixing it seems so hopeless. "You've got hospitals doing what's good for hospitals, HMOs doing what's good for HMOs, and drug companies doing what's good for them," Avorn says. "We've got this crazy patchwork, with everyone against everyone else, and you end up with these paradoxes like Nexium."
So How Do We Stop This Drug Cycle From Truly Spiraling Out Of Control?
For insurers, the answer seems to be learning to say no a lot more. Most are implementing aggressive cost-control programs, such as "prior authorization," in which doctors have to obtain approval from the insurer before putting a patient on a particularly expensive drug when there are comparable, cheaper drugs available.
MassHealth, the state's Medicaid program for the poor, spent $25 million on Prilosec last year. In August, it stopped paying for the drug unless a doctor could prove that a patient needed it over a cheaper alternative. Harvard-Pilgrim Health Care, Tufts Health Plan, and Blue Cross Blue Shield have all introduced their own prior authorization programs. But in a system already larded with excessive bureaucracy, few see this as the right way out. Avorn calls it the "1-800-NO-YOU-CAN'T" route.
Also, because each insurer is out there cutting its own deals with all the various drug manufacturers and pharmacy benefits managers, there's little consistency in restrictions. Tufts, for instance, drew fire from many of its members a few years ago when it said no to Claritin. But because it got a good deal on Nexium, the new Purple Pill is not on Tufts's prior authorization list.
What seems clear is that consumers will soon be much more aware of what drugs actually cost, because insurers and employers will be passing on a much bigger chunk of the bill. It won't be a matter of a $25 copay rather than $10. They will either have to be prepared to pay full freight for the Cadillac or get used to riding in the Hyundai.
Some answers may lie in Washington, D.C. For years, the drug manufacturers have protected their interests by sharing their wealth with congressional campaign committees. But in the face of public anger - anger that will only intensify as premiums continue to rise and insurers say "No" more often - such protection only goes so far.
Federal regulators recently announced a plan to crack down on the most flagrant wining and dining of doctors by drug companies. But it's not at all clear that anyone has the stomach for real revolution, such as having an independent body with the consumers' interests in mind take over the entire testing process for new drugs.
There is momentum elsewhere, though. Last month, President Bush proposed new rules aimed at limiting the ability of brand-name drug makers to stall generics. And last year, John McCain and Charles Schumer persuaded colleagues in the US Senate to pass an even tougher measure designed to curb all those patent lawsuits that the Hatch-Waxman Act unwittingly spawned.
Though it's been stalled in the House, the measure is being pushed aggressively by a coalition of consumer groups and some of Big Business's biggest guns - General Motors, Wal-Mart, Motorola - which bear much of today's health care costs. "We've zeroed in on Prilosec," says Brad Cameron, a Washington lobbyist leading the charge on behalf of the coalition. "We've got to find a way to close these most egregious loopholes."
Then
again, it may not be wise to bet against the purple powerhouse that has
defied every expectation since its launch. The 39-year-old Cameron has had
heartburn since he was in college. He confesses that when his symptoms got
worse recently, he went to see his doctor. "My best friend's on Prilosec," he told his doctor. "It works for him.
How about Prilosec for me?"
Why Inhibiting Acid Production with Prilosec, Prevacid and Nexium Could Make Matters Worse
A recent online survey of over 4200 patients taking Priolosec, Prevacid or Nexium found:
- 35% to 41% of the respondents continue to experience daily heartburn symptoms.
- 60% of the respondents reported experiencing symptoms three or more times per week.
- 75% of PPI patients also take nonprescription medications, such as Pepcid, Maalox and Tums.
- 25% of the respondents said they take over-the-counter medications in place of their prescription medication.
These drugs, and others like them, clearly are effective at what they do or there is no way in the world these companies could convince people to buy them. BUT they DO NOT solve the problem. In fact, they actually worsen it.
Then, when you are using the wrong solution for the problem, you are bound to have problems. Drugs are rarely, if ever, indicated for the common ulcer and associated stomach problems. The proton pump inhibitors like Prevacid and Prilosec and the H2 blocker agents like Tagament, Pepcid, and Zantac are some of the worst drugs that you could possible take.
Why?
They significantly reduce the amount of acid you have and with that your ability to properly digest food. Reduction of acid in the stomach also diminishes your primary defense mechanism for food borne infections and will increase your risk of food poisoning.
University
of Michigan scientists found that antibiotics were the best way to kill the
bacteria that cause gastritis and eliminate stomach inflammation in their
experimental mice. Mice treated with prescription drugs called proton pump
inhibitors or PPIs, like Prilosec,
Prevacid and Nexium, which
block acid production, acquired more bacteria and developed more inflammatory
changes in their stomach linings than untreated mice.
These animal studies indicate that it is the inflammatory response - triggering the overproduction of hydrochloric acid, which is the stomach's primary response to bacterial colonization. Inflammation of the stomach lining coincides with production of peptides called cytokines, which stimulate production of a hormone called gastrin.
Gastrin
triggers parietal cells in the stomach lining to produce more hydrochloric
acid, which kills off most invading microbes. If you inhibit gastric acid
production, you interfere with the stomach's natural defense mechanism."
Since
reduced gastric acidity does appear to make the mammalian stomach more vulnerable
to bacterial invasion and gastritis, Physicians may want to re-evaluate the
long-term use of the Purple Pill and other proton-pump-inhibiting drugs
in their patients.
Mice
contracted gastritis just like people do - from eating food or drinking water
contaminated with bacteria. While 75 percent of people with gastritis test positive for
Helicobacter pylori, many other
species of bacteria can trigger inflammatory changes, too, and often co-exist
with Helicobacter.
The
findings show that changes observed in gastrin-deficient
mice are caused by inflammation triggered by an overgrowth of many bacterial
species. An abnormally low level of acidity in the stomach is the factor
initiating all these events.
No
matter what type of bacteria causes the problem, it is a serious medical
condition. If untreated, chronic gastritis can lead to peptic ulcers and
stomach cancer.
Also,
within medical records of some 500,000 patients, researchers found that those
using acid-suppressive drugs to treat heartburn and indigestion were four times
more likely to have pneumonia than nonusers.
Researchers
concluded that using acid-suppressive drugs is associated with the increased
risk of community-acquired pneumonia. Further, current use of these drugs
doubles the risk of pneumonia.
Can
it get any worse?
A
US advisory panel on June 21 urged approval for Procter & Gamble Co.'s bid
to sell AstraZeneca wildly popular drug Prilosec without a prescription. The recommendation now
goes to the US Food and Drug Administration, which usually follows its panels'
advice. Prilosec, marketed as the "purple
pill," is one of the world's best-selling medicines.
If
approved, Prilosec would be the first of a group of
acid-blocking drugs known as proton pump inhibitors to be available over the
counter.
Procter
& Gamble, which owns the rights to an OTC form of Prilosec,
wants to market the nonprescription version for preventing frequent bouts of
heartburn, defined as occurring two or more days per week.
About
40 million Americans experience frequent heartburn. Procter & Gamble
predicts annual
US sales of between $200 million and $400 million for nonprescription Prilosec.
Proposed
directions for nonprescription Prilosec would urge
people to take one tablet daily, in the morning, for 14 days to prevent
frequent heartburn.
A Natural Solution for Heartburn
In
some ways it is wonderful to see these drugs go OTC because that will lower the
price for people who might need this drug.
Folks,
I can assure you the number of people who actually need this drug is less than
1 in 100 of those taking it. In other words, people are being prescribed drugs
for heartburn when it is one of the easiest medical problems to treat. Most
people ignore heartburn as an important clue from their body and rely on a drug
to further suppress the symptoms.
This
is the equivalent of driving your car and ignoring the idiot light that comes
on your dashboard warning you of a problem. Using a band-aid like Prilosec to cover the light allows you to ignore the
problem and although it may solve the problem in the short-term, the
implications for ignoring this important clue are quite obvious as you could be
looking far more costly repairs by not acknowledging the symptom.
So what is the solution for heartburn?
There
are several key points:
- Drink adequate
amounts of clean water (drink a large glass of water at the first sign of
heartburn).
- Follow a careful diet
careful to avoid sugar and those things, which can trigger your
heartburn…spicy foods, fatty or fried foods, alcohol, coffee, carbonated
beverages, citrus fruits, chocolate or tomato-based foods. Eat more raw vegetables, chew your food,
eat slowly, and do not eat 3 hours before bedtime.
- Drink 2-4 tablespoons
of apple cider vinegar before each meal (if you still have heartburn, then
you are the 1 out of 1000 people that do have too much acid in your
stomach and can benefit from the purple pill).
- Take digestive
enzymes specifically with beatine hydrochloric
acid (ForMor’s MEC Multi-Enzyme
Complex)
- Drink aloe vera juice and take MSM (ForMor’s
Nutragenix contain both of these
ingredients, which help coat and heal the entire digestive track).
- Use 1-2 cloves of raw
fresh garlic per day to eradicate H. pylori, which is a factor for many
with heartburn.
- Use high quality probiotics specifically acidophilus and bifidus bacteria.
These are living cultures of live, good bacteria and must be
refrigerated after opening the bottle.
(ForMor’s Argenix contains be flora, which is a prebiotic and will multiply the good bacteria in your
colon by 5 times).
Conclusion
Heartburn
is not a disease as Big Pharma want you to
believe. For anyone over 40 it begins to
reveal itself because our stomachs production of hydrochloric acid begins to
decrease. It is simply acid that is
misplaced in your digestive track because your stomach can no longer digest
food as it use to when you were young.
By
simply following the natural remedies I outlined above, you can live a life
free from having heartburn and free from wearing Purple Pampers!